Investigating genetic variants in a protein linked to a common type of glaucoma
The Structural and Biochemical Effects of XFG-Associated Variants in LOXL1
This study is looking at a protein linked to pseudoexfoliation glaucoma to see how different versions of it might affect the condition, which could help patients understand more about their eye health and vision loss.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10903489 on NIH RePORTER |
What this research studies
This research focuses on understanding the structural and biochemical properties of a protein called LOXL1, which is associated with pseudoexfoliation glaucoma (XFG). By examining both the normal and variant forms of LOXL1, the study aims to uncover how these genetic differences contribute to the development of XFG, a condition that can lead to vision loss. The research employs advanced techniques such as biomolecular nuclear magnetic resonance to analyze the protein's structure and function. Patients with XFG may benefit from insights gained about the underlying mechanisms of their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pseudoexfoliation glaucoma or those with genetic variants linked to this condition.
Not a fit: Patients without pseudoexfoliation glaucoma or those not carrying the associated genetic variants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and potential new treatments for patients suffering from pseudoexfoliation glaucoma.
How similar studies have performed: Previous research has shown promising results in understanding genetic factors in glaucoma, suggesting that this approach could yield valuable insights.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Youngblood, Hannah Abigail — Georgia Institute of Technology
- Study coordinator: Youngblood, Hannah Abigail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.